Tepotinib with Gefitinib in Subjects with Locally Advanced or Metastatic NSCLC (INSIGHT)

Update Il y a 5 ans
Reference: EUCTR2016-001604-28

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Phase Ib  To determine the RP2D of tepotinib when used in combination with gefitinib (at the approved standard dose of 250 mg) when administered orally once daily over a 21-day cycle in subjects with MET+ advanced NSCLC. Phase II To evaluate whether the efficacy in terms of progression free survival (PFS) of second-line tepotinib in combination with gefitinib is superior to pemetrexed+cisplatin/carboplatin in subjects with T790M negative, MET+ locally advanced or metastatic NSCLC harboring an EGFR mutation and having acquired resistance to first-line EGFR-TKI therapy including gefitinib, erlotinib, icotinib, or afatinib


Inclusion criteria

  • Locally advanced or metastatic non-small cell lung cancer (NSCLC)

Links